Prescription ·Strong evidence ·Reviewed May 2026
Clonidine is a centrally acting alpha-2 adrenergic agonist used for hypertension, including resistant hypertension, and for several off-label and approved indications such as ADHD, opioid and alcohol withdrawal symptoms, and menopausal hot flashes. It lowers blood pressure by reducing central sympathetic outflow, which decreases peripheral vascular resistance and heart rate. Abrupt discontinuation can cause dangerous rebound hypertension, so it must be tapered.
The bottom line
Evidence rating strong. Most-documented uses: hypertension, including resistant hypertension as add-on therapy, attention-deficit/hyperactivity disorder (extended-release formulation), management of opioid withdrawal autonomic symptoms. 3 sources indexed (1978–2012), with 6 interaction records on file.
Core mechanism
Clonidine stimulates presynaptic alpha-2 adrenergic receptors in the brainstem vasomotor center (notably the nucleus tractus solitarius and locus coeruleus). Activating these autoinhibitory receptors reduces sympathetic nervous system outflow from the central nervous system, lowering norepinephrine release. The result is reduced peripheral vascular resistance, decreased heart rate, and lower blood pressure. The same central sympatholytic and locus coeruleus effects account for its sedative properties, its ability to blunt autonomic hyperactivity during opioid or alcohol withdrawal, and its modulation of attention and arousal in ADHD. Clonidine also has partial agonist activity at imidazoline receptors, which may contribute to its antihypertensive effect.2,1
Well absorbed orally with bioavailability around 75-100 percent; may be taken with or without food. Clonidine is lipophilic enough to cross the blood-brain barrier and is also delivered transdermally. Largest oral dose is often given at bedtime to limit daytime sedation.2
Melatonin can add to clonidine-related sedation, dizziness, and blood pressure lowering.
Recommendation: Avoid driving or hazardous tasks until effects are known; monitor for morning sedation, falls, or symptomatic hypotension.
L-Theanine may add to clonidine-related sedation or blood pressure lowering.
Recommendation: Use cautiously and avoid combining with alcohol or other sedatives unless clinician-reviewed.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Clonidine.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
Ashwagandha (Withania somnifera) has central calming and mild sedative-anxiolytic properties and may potentiate the sedation and drowsiness produced by clonidine, a centrally acting alpha-2 agonist. The combination can increase daytime somnolence and impair alertness, particularly during dose initiation or up-titration.
Recommendation: Use together cautiously. Watch for excessive drowsiness, slowed reaction time, and fatigue, especially when starting either agent or increasing the clonidine dose. Avoid driving or operating machinery until the combined effect is known. Consider taking ashwagandha at bedtime rather than during the day.
L-Tryptophan, a serotonin precursor, has sedative and sleep-promoting effects that can add to the somnolence caused by clonidine. The combination may produce greater than expected drowsiness and impaired alertness.
Recommendation: Use cautiously together. Monitor for excessive sedation and impaired psychomotor performance; advise against driving until effects are known. Prefer bedtime dosing of L-tryptophan and avoid combining with other sedating agents.
Potassium supplementation can produce a modest reduction in blood pressure that is generally complementary to clonidine therapy in hypertensive patients. The interaction is usually beneficial but warrants attention to overall blood pressure control and serum potassium.
Recommendation: Adequate potassium intake supports blood pressure management and is typically compatible with clonidine. Monitor blood pressure and serum potassium periodically, particularly in patients with renal impairment or those taking potassium-sparing agents, to avoid hyperkalemia or excessive blood-pressure lowering.
Numbered references. Citations throughout the page link here.
Clonidine suppressed many of the autonomic signs and symptoms of opioid withdrawal, consistent with reduced noradrenergic locus coeruleus activity.
Clonidine reduces blood pressure through central alpha-2 receptor stimulation and decreased sympathetic outflow; abrupt cessation can cause rebound hypertension, so the dose should be tapered over 2 to 4 days.
Extended-release clonidine, alone or as adjunct to stimulants, significantly reduced ADHD symptom scores versus placebo, with somnolence and sedation as the most common adverse effects.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
